Cyrus Daruwalla

Cyrus Daruwalla

Auto-generated profile, based on publicly available information

Cyrus Daruwalla

Medicine, NYU Grossman School of Medicine, New York, New York, USA

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2021 in Survey of Ophthalmology
Verified
Journal Article
Closed access
SWSydney Wendt
Sydney Wendt
ZAZainub Abdullah
Zainub Abdullah
SBSpencer Barrett
Spencer Barrett
CDCyrus Daruwalla
Cyrus Daruwalla
JGJonathan A. Go
Jonathan A. Go
ALAndrew G Lee
Andrew G Lee

9 July 2026 in Gut
Verified
Journal Article
Closed access
PDF file
CDCyrus Daruwalla
Cyrus Daruwalla
ECEvelyn Calderon
Evelyn Calderon
CMChristo Mathew
Christo Mathew
LMLauren Mignogna
Lauren Mignogna
AVAjit Vyas
Ajit Vyas
RHRuben Hernaez
Ruben Hernaez
Background: Locoregional therapy (LRT) is frequently used as bridging therapy to transplantation/resection or palliative treatment for hepatocellular carcinoma (HCC). Multiple prediction models have been developed for prognosis and treatment response among patients undergoing LRTs. Objective: We aimed to systematically review the methodological quality and performance of clinical risk scores predicting outcomes in patients with HCC treated with LRT. Design: EMBASE and PubMed were searched from inception to 18 March 2026. Our main outcome was the concordance statistic, or area under the receiver operating characteristic curve (AUROC), to predict survival and other tumour-related and liver-related outcomes. Results: 130 studies met the inclusion criteria, resulting in 179 individual scoring systems. The total population was 70 061 patients, 21% female (4–51%), most with Barcelona Clinic Liver Cancer Stage B (39%). Risk scores commonly incorporated tumour parameters, liver function tests, cirrhosis staging and comorbidities. AUROC values ranged from 0.56 to 0.94. 16 studies (12.3%) had low risk of bias, while most had high risk of bias. Of these, the Y-scoring system, Cheng et al nomogram and Li et al nomogram showed the highest discrimination for overall survival in palliative LRT (AUROC >0.87). Separate pooled analyses showed that the Hepatoma Arterial-embolisation Prognostic (HAP) and modified Hepatoma Arterial-embolisation Prognostic II (mHAP-II) scores had the highest performance (pooled AUROC >0.72), while the Six-and-Twelve (0.68) and Albumin-Bilirubin (ALBI) scores (0.60) demonstrated lower performance. Conclusion: Several outcome scoring systems are promising for specific LRTs and populations. However, most models have high risk of bias, underscoring the need for further development and validation.